Outset Medical, Inc. ( OM) Stock. Should you Buy or Sell? $ 18.74
0.85 (4.34 %)
Outset Medical, Inc. Analysis
Updated on 10-09-2022| Symbol | OM |
| Price | $18.74 |
| Beta | 0.000 |
| Volume Avg. | $726.96 thousand |
| Market Cap | $899.66 M |
| 52 Week Range | $13.25 - $60.33 |
Outset Medical, Inc. opened the day at $18.74 which is +'4.34 % on yesterday's close. Outset Medical, Inc. has a 52 week high of $60.33 and 52 week low of $13.25, which is a difference of $47.08. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $899.66 M and total net profit is $102602000 which means the company is trading at 8.77 times profit to market capitalization. Theoretically, if you were to buy Outset Medical, Inc. for $899.66 M, it would take 15 years to get your money back. Outset Medical, Inc. are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Outset Medical, Inc. Stock Forecast - Is Outset Medical, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -5.887 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -1.385 |
Valuing Outset Medical, Inc.
| Price Book Value Ratio | 2.897 | Price To Book Ratio | 2.897 |
| Price To Sales Ratio | 8.152 | Price Earnings Ratio | -5.887 |
How liquid is Outset Medical, Inc.
| Current Ratio | 6.260 |
| Quick Ratio | 5.190 |
Debt
| Debt Ratio | 0.228 | Debt Equity Ratio | 0.295 |
| Long Term Debt To Capitalization | 0.102 | Total Debt To Capitalization | 0.107 |
Latest news about Outset Medical, Inc.
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2022 at 11:55am PT / 2:55pm ET. A live and archived webcast of the fireside chat will be available on the “Investors” section of the
Outset Medical, Inc. (NASDAQ:OM ) Q2 2022 Earnings Conference Call August 1, 2022 5:00 PM ET Company Participants Jim Mazzola - Vice President Investor Relations Leslie Trigg - Chair & Chief Executive Officer Nabeel Ahmed - Chief Financial Officers Conference Call Participants Travis Steed - Bank of America Josh Jennings - Cowen Suraj Kalia - Oppenheimer Rick Wise - Stifel Phil Coover - Goldman Sachs Drew Ranieri - Morgan Stanley Josh Jennings - Cowen Operator Greetings, and welcome to Outset Medical Q2 2022 Earnings Conference Call. At this time, all participants are in listen-only mode.
A major FDA decision clears the way for Outset to again go after a huge opportunity.
Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -22.22% and 2.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
The mean of analysts' price targets for Outset Medical, Inc. (OM) points to a 93.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
About Outset Medical, Inc.
Description :
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
